H.R. 198 · 118th Congress (2023–2025)
Drug Pricing Transparency and Accountability Act
This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.
Show official title
To increase reporting requirements and transparency requirements in the 340B Drug Pricing Program, and for other purposes.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 198’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Matthew M. Rosendale Sr. (R-MT-2)
- Policy area
- Health
- Subjects
- Administrative law and regulatory procedures
- Congressional oversight
- Department of Health and Human Services
- Government information and archives
- Government studies and investigations
- Health facilities and institutions
- Health information and medical records
- Home and outpatient care
7 more
- Hospital care
- Medicaid
- Medicare
- Prescription drugs
- Public contracts and procurement
- Public-private cooperation
- State and local government operations
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 3 committee actions · Jan 9, 2023 – Dec 17, 2024
Referred to committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Drug Pricing Transparency and Accountability Act
Display title, Short title · Introduced in House
To increase reporting requirements and transparency requirements in the 340B Drug Pricing Program, and for other purposes.
Official title · Introduced in House